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### Drug-Coated Balloons for Coronary Artery Disease: Third Report of the International DCB Consensus Group {#sec1.1.1}
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This is the third report of the International DCB Consensus Group summarizing current recommendations on the use of drug-coated balloons (DCB). DCB are a novel treatment strategy for coronary artery disease. Their use is established for in-stent restenosis of both bare-metal and drug-eluting stents, and recent randomized clinical data demonstrate a good efficacy and safety profile in de novo small-vessel disease and high bleeding risk, besides other emerging indications such as bifurcation lesions, large-vessel disease, diabetes mellitus, and acute coronary syndromes.
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### Optimal Stenting Technique for Complex Coronary Lesions: Intracoronary Imaging-Guided Pre-Dilation, Stent Sizing, and Post-Dilation {#sec2.1.1}
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In patients receiving drug-eluting stenting for complex coronary lesions including left main coronary artery lesion, bifurcation lesion, diffusely long lesion, and angiographically severely calcified lesion, intracoronary imaging--guided pre-dilation, stent sizing, and post-dilation was associated with a significant reduction of 3-year rates of primary composite outcome of cardiac death, target vessel myocardial infarction, or target vessel revascularization (5.6% vs. 7.9%; adjusted hazard ratio: 0.71; 95% confidence interval: 0.63 to 0.81; p \< 0.001).
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### EDITORIAL COMMENT Optimal Stenting Is the Gold Standard: We Have Plenty of Data and New Questions Arise {#sec2.1.2}
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### Coronary Calcification and Long-Term Outcomes According to Drug-Eluting Stent Generation {#sec2.1.3}
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The authors pooled data on 19,833 patients from 18 randomized trials evaluating outcomes after percutaneous coronary intervention, categorized according to the presence of angiography core laboratory--confirmed moderate or severe coronary artery calcification in any target lesion. Coronary artery calcification was significantly associated with an increase in 5-year adverse events. Second-generation drug-eluting stents compared with first-generation drug-eluting stents were associated with significant reductions in the 5-year risks for target lesion failure and stent thrombosis in patients with target lesion moderate or severe coronary artery calcification.
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### EDITORIAL COMMENT Coronary Calcifications in Patients Undergoing PCI: The Forgotten Enemy Back in the Spotlight {#sec2.1.4}
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### Clinical Outcomes Following Coronary Bifurcation PCI Techniques: A Systematic Review and Network Meta-Analysis Comprising 5,711 Patients {#sec2.1.5}
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Provisional stenting has been recommended as the default technique for most coronary bifurcation lesions. The aim of this study was to compare clinical outcomes of different bifurcation percutaneous coronary intervention (PCI) techniques by means of a network meta-analysis. Twenty-one randomized controlled trials including 5,711 patients treated with 5 bifurcation PCI techniques (provisional, crush, culotte, T stenting/T and protrusion, and double-kissing crush). After a median follow-up period of 12 months (interquartile range: 9 to 36 months), the double-kissing crush technique had less occurrence of major adverse cardiovascular events (odds ratio: 0.39; 95% credible interval: 0.26 to 0.55) compared with provisional stenting. This difference was driven by a reduction in target lesion revascularization (odds ratio: 0.36; 95% credible interval: 0.22 to 0.57). No differences were found in cardiac death, myocardial infarction, and stent thrombosis among analyzed PCI techniques.
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### EDITORIAL COMMENT Complex Better Than Simple for Distal Left Main Bifurcation Lesions: Lots of Data But Few Crushing Operators {#sec2.1.6}
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### Intravascular Healing Is Not Affected by Approaches in Contemporary CTO PCI: The CONSISTENT CTO Study {#sec2.1.7}
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The adoption of dissection and re-entry techniques (DART) means that success rates of \>90% are achievable for unselected coronary chronic total occlusions (CTO). The impact of DART and subintimal stenting on the durability of CTO procedures is poorly understood. A low rate of target vessel failure (composite of cardiac death, myocardial infarction related to the target vessel, or any ischemia-driven revascularization) for CTO lesions was observed at 12 and 24 months. DART did not adversely affect intravascular healing assessed using optical coherence tomography at 12 months or clinical events at 2 years.
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### EDITORIAL COMMENT Back to the Future: Intravascular Imaging to Assess and Guide CTO PCI Procedures {#sec2.1.8}
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### Routine Ultrasound or Fluoroscopy Use and Risk of Vascular/Bleeding Complications After Transfemoral TAVR {#sec3.1.1}

[1460](http://linkinghub.elsevier.com/retrieve/pii/S1936-8798(20)30870-0){#intref0055}

Guy Witberg, Vasileios Tzalamouras, Heath Adams, Tiffany Patterson, Ross Roberts-Thomson, Jonathan Byrne, Rafal Dworakowski, Philip MacCarthy, Simon Redwood, Bernard Prendergast

The study compared periprocedural vascular or bleeding complications in patients undergoing transfemoral transcatheter aortic valve replacement at 2 high-volume referral centers in London, United Kingdom, during 2014 to 2018. One center routinely used 2-dimensional ultrasound (2D-US) for guiding femoral arterial puncture, whereas the used other fluoroscopy and contralateral angiography (FCA). The sample size was 1,171 patients. Rates of vascular complications, bleeding, and their composite were similar among the groups (6.7% vs. 6.8%, p = 0.63; 6.1% vs. 6.4%, p = 0.70; and 9.8% vs. 9.8%, p = 0.76, respectively). The results show that excellent outcomes can be achieved using either 2D-US or FCA in high-volume, experienced centers.
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### EDITORIAL COMMENT Vascular Access Site for TAVR: Use the Approach You Master Best {#sec3.1.2}
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### Safety and Efficacy of Protamine Administration for Prevention of Bleeding Complications in Patients Undergoing TAVR {#sec3.1.3}
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Bleeding complications in patients undergoing transcatheter aortic valve replacement are associated with increased mortality. The aim of this study was to evaluate whether protamine administration for heparin reversal reduces complications and affects patient outcomes. The primary endpoint, a composite of 30-day mortality and life-threatening and major bleeding, occurred less frequently in the protamine administration group (3.2%) than the control group (8.7%) (p = 0.003), driven mainly by lower rates of life-threatening (0.1% vs. 2.6%) and major (1.0% vs. 4.1%) bleeding. Protamine administration resulted in a significantly shorter hospital stay (delta 1.6 days). However, occurrence of thromboembolic events was not increased by protamine administration.

### EDITORIAL COMMENT Protamine in Patients Undergoing Transcatheter Aortic Valve Replacement: Why Not? {#sec3.1.4}
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### Triage Considerations for Patients Referred for Structural Heart Disease Intervention During the COVID-19 Pandemic: An ACC/SCAI Position Statement {#sec4.1.1}
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The coronavirus disease-2019 (COVID-19) pandemic has strained health care resources around the world, causing many institutions to curtail or stop elective procedures. This has resulted in an inability to care for patients with valvular and structural heart disease in a timely fashion, potentially placing these patients at increased risk for adverse cardiovascular complications, including CHF and death. The effective triage of these patients has become challenging in the current environment as clinicians have had to weigh the risk of bringing susceptible patients into the hospital environment during the COVID-19 pandemic against the risk of delaying a needed procedure. In this document, the authors suggest guidelines for how to triage patients in need of structural heart disease interventions and provide a framework for how to decide when it may be appropriate to proceed with intervention despite the ongoing pandemic. In particular, the authors address the triage of patients in need of transcatheter aortic valve replacement and percutaneous mitral valve repair. The authors also address procedural issues and considerations for the function of structural heart disease teams during the COVID-19 pandemic.
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### Angiographic Findings of the Development of a Reverse Blood Supply After Percutaneous Deep Venous Arterialization {#sec5.1.1}
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### Should We Protect the Coronary Artery During Transcatheter Aortic Valve Replacement in Quadricuspid Valve Patients? {#sec5.1.2}
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### ONLINE FEATURE Spontaneous Coronary Artery Dissection in a Patient With COVID-19 {#sec5.1.3}
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### To the Editor Subclassification of *CYP2C19* Genotyping for Better-Adjusted Thienopyridine Treatment {#sec6.1.1}
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### To the Editor A Claim for Consensus {#sec6.1.3}
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### Research Correspondence Evolving Technique for SAPIEN Pulmonary Valve Implantation: A Single-Center Experience {#sec6.2.2}
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